An economic evaluation of cabazitaxel versus a second androgen receptor-targeted agent (ARTA) for patients with metastatic castration-resistant prostate cancer previously treated with docetaxel and an ARTA: the United States payer perspective

Table 3 Number of patients in rPFS, PFS, and OS at 6, 12, and 24 months

Outcome	6 months			12 months			24 months
Outcome	Cabazitaxel	Second ARTA	Difference	Cabazitaxel	Second ARTA	Difference	Cabazitaxel	Second ARTA	Difference
rPFS (number of patients)	58	36	22	27	9	18	6	4	2
PFS, (number of patients)^a	36	16	21	10	3	7	0	0	0
OS, (number of patients)	86	81	5	56	45	12	25	9	16
Hospitalization days	112	138	−26	206	250	−44	297	351	−54
ICU days	5	7	−2	6	8	−2	7	8	−1

Abbreviations: ARTA androgen receptor-targeted agent, ICU intensive care unit, OS overall survival, PFS progression-free survival, rPFS radiographic progression free survival
Values correspond to a cohort of 100 patients for each treatment
^aNo results available for 24 months as the number at risk for PFS was 0 for both arms in the CARD trial

ISSN: 1472-6963